- Title: Subtitle
- O4-2. Clinical factors related to cytokine release syndrome and elranatamab dosing recommendations after a dose interruption
- Creators
- Mohamad MohtyRuben NiesvizkyBertrand ArnulfAjay K. NookaSalomon ManierMichael H. TomassonNizar J. BahlisDonald IrbyJennifer E. HibmaAndrea ViqueiraEric LeipAlexander M. LesokhinINSERM UMRs
- Resource Type
- Abstract
- Publication Details
- International Journal of Myeloma, Vol.14(3), pp.98-98
- Publisher
- The Japanese Society of Myeloma
- Language
- Japanese
- Date published
- 2024
- Academic Unit
- Health and Human Physiology; Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984721441902771
Abstract
O4-2. Clinical factors related to cytokine release syndrome and elranatamab dosing recommendations after a dose interruption
International Journal of Myeloma, Vol.14(3), pp.98-98
2024
Details
Metrics
1 Record Views